Can next-generation antibodies offset biosimilar competition? Nature.com Pfizer, more recently, has joined Teva, Novartis, Merck & Co. and others in disclosing that it is testing a biosimilar version of Roche's blockbuster anti-CD20 mAb rituximab in patients. So although there is no stark mAb patent cliff looming on the ... |
